Remove Patients Remove Pharmaceutical Remove Treatment
article thumbnail

Clinical Trial: Cannabinoid Administration Via a Metered-Dose Inhaler Is Safe and Effective for Chronic Pain Patients

NORML

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Participants inhaled a precise dose containing either THC (at doses of either 0.5mg or 1mg) or placebo. .”

article thumbnail

The Cannabis Cancer Connection

Project CBD

I advise my patients to stop using cannabis for 36 to 48 hours prior to chemotherapy and to start again 36 to 48 hours after their session. Phase 2 is the first study level conducted on patients with the disease for which the drug is intended and determines whether it is safe and effective.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Can Cannabis Help Patients Titrate Off Other Pharmaceutical Drugs?

United Patients Group

Cannabis is a natural treatment for pain and other symptoms of withdrawal, and has been shown to help manage the side effects of drugs and even has be used as a substitute for prescription medications. Cannabis is a natural treatment for pain and other symptoms of withdrawal. 3] Cannabis is safer than prescription drugs.

article thumbnail

What's at Stake in the 2024 Election?

Americans for Safe Access

A letter from ASA Founder & President The positive impacts of medical cannabis on patients and the healthcare systems that serve them are profound and far-reaching. territories, often serving as a crucial alternative when conventional treatments have failed or as a safer option compared to pharmaceuticals.

Therapy 212
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

article thumbnail

This app-guided psychedelic treatment works when antidepressants don’t

The Cannigma

When antidepressants were first introduced in the mid-20 th century, they were a breakthrough in pharmaceuticals. Of the people who take antidepressants, 30% won’t respond to treatment. But what other options do people suffering from depression, particularly treatment-resistant depression, have? What is ketamine treatment?

Treatment 140
article thumbnail

Prohibition Publish 2nd Ed Of The Pharmaceutical Cannabis Report

Cannabis Law Report

The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products.